rAvPAL-PEG

DRUG3 trials

Sponsors

BioMarin Pharmaceutical

Conditions

Phenylketonuria

Phase 1

Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

CompletedNCT00634660

BioMarin PharmaceuticalPhenylketonuria

Start: 2008-05-31End: 2009-10-31Updated: 2017-02-01

Phase 2

Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

CompletedNCT00924703

BioMarin PharmaceuticalPhenylketonuria

Start: 2010-01-13End: 2019-01-31Updated: 2021-10-12

Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)

CompletedNCT01212744

BioMarin PharmaceuticalPhenylketonuria

Start: 2011-03-31End: 2015-04-30Updated: 2019-02-26

Related Papers

Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program.

2024-04-239 citations

Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.

2020-06-1622 citations

Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.

2018-07-0426 citations